RxDoctor Payments Data

David Moore, MD

Gastroenterology · Bountiful, UTNPI 1215969837

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 305 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 53.4% of the total.

$4,044in general payments, 2019–2025

Across 305 payments — averaging $13.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$545
  • Takeda Pharmaceuticals U.S.A., Inc.$282
  • Pfizer$210
  • Bristol Myers Squibb$128
  • Regeneron Healthcare Solutions, Inc.$85
  • plus $632 from 22 others

What the payments were for

  • Food & beverage$4,029100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,044 in reported general payments places this provider in the 65th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah

Medicare billing

Part B allowed, 2024
$118,875
Medicare patients
286
Services billed
2,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$354,887
LinzessLinaclotide19$14,203
Balsalazide Disodium19$3,211
Omeprazole133$2,475
Sucralfate17$1,634
Pantoprazole Sodium43$736
Famotidine34$604
Rabeprazole Sodium12$592
Olanzapine12$358
Ondansetron Hcl23$283
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl15$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$545$354,88713 claims
AbbVieLinzess$2,162$14,20319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 122 gastroenterology providers in Utah.

Other gastroenterology in Bountiful

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →